Neuronetics names Steven Pfanstiel as new chief financial officer

Neuronetics Inc. (NASDAQ: STIM) appointed Steven Pfanstiel as chief financial officer, effective July 15, 2025, according to a company statement. Pfanstiel replaces Steve Furlong, who announced his intention to retire on March 31, 2026.

Furlong will remain with the medical technology company as senior advisor to the CEO until the end of March 2026 to ensure a smooth transition. He served as CFO for six years.

Pfanstiel brings over two decades of healthcare experience to the role. He most recently served as CFO and COO at publicly-traded Marinus Pharmaceuticals prior to its acquisition by Immedica Pharma AB in February 2025. At Marinus, he played a role in the commercial launch of Ztalmy, the company's product.

Previously, Pfanstiel held senior financial leadership positions at Lifescan and Optinose, which was acquired by Paratek Pharmaceuticals. Earlier in his career, he worked in progressively senior finance roles at Johnson & Johnson across pharmaceuticals, orthopedics, and diabetes divisions.

Pfanstiel holds a Bachelor of Arts in Physics from Wabash College, an MBA in Finance from Indiana University's Kelley School of Business, and a Master of Science in Environmental Systems Engineering from Clemson University.

As part of his employment, Pfanstiel received an inducement grant of 400,000 restricted stock units. Half of the units vest in equal installments on the first, second, and third anniversary of his start date, while the remaining units vest in equal installments on the second, third, and fourth anniversary, subject to continued employment.

The company reaffirmed its guidance for the second quarter and full year 2025. Neuronetics stated it remains positioned to achieve positive cash flow in the third quarter of 2025.

You May Also Be Interested In

• Valion Bio names board member Dean Zikria as interim CEO
• Surf Air Mobility names Palantir veteran as president of SurfOS
• Flywire adds ex-GitLab CTO Sabrina Farmer to its board